| Literature DB >> 19889225 |
Sergio V Cardoso1, Kelen Christine N Souza, Paulo R Faria, Ana Lucia A Eisenberg, Fernando L Dias, Adriano M Loyola.
Abstract
BACKGROUND: Information on the biology of metastasis development in salivary gland tumors is scarce. Since angiogenesis seems associated with this phenomenon in other tumors, we sought to compare salivary gland tumors with diverse metastatic behavior in order to improve the knowledge and management of these lesions.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19889225 PMCID: PMC2777937 DOI: 10.1186/1471-2407-9-391
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Clinical and demographic data
| Sex | Age | |
|---|---|---|
| Class or type of tumor | (male:female) | (years, mean ± SD) |
| 1:1.5 | 52.0 ± 13.8 | |
| 1:1.5 | 50.3 ± 17.1 | |
| 1:1.9 | 49.6 ± 17 | |
| 1:0.4 | 54.5 ± 17.6 | |
| 1:1.8 | 51.2 ± 16.6 | |
| 1:1.1 | 61.1 ± 13.3 | |
| 1:1.5 | 44.8 ± 17.9 | |
Figure 1Distribution of metastasizing tumors, according to histological type and site of metastatic implants.
Figure 2Frequency of cases with positive staining for CD105, according to: A. biological behavior; and B. histological type.
Figure 3Intratumoral microvessel density (IMD), evaluated by CD105 staining, according to biological behavior and histological type.
CD105 immunohistochemical localization in primary salivary gland tumors (IMD = intratumoral microvessel density) [14].
| CD105 positivity | |||
|---|---|---|---|
| Type and metastatic status | Frequency | IMD (mean ± SD) | |
| Primary, non-metastasizing | 41 | 2.4% | 0 |
| Primary, metastasizing | 10 | 30.0% | 0.7 (± 1.3) |
| Primary, non-metastasizing | 17 | 47.1% | 1.6 (± 2.0) |
| Primary, metastasizing | 2 | 0 | 0 |
| Primary, non-metastasizing | 36 | 83.3% | 4.8 (± 6.0) |
| Primary, metastasizing | 4 | 100% | 6.2 (± 2.1) |
Figure 4Immunohistochemical staining of CD105 in salivary gland tumors (streptavidin-biotin-peroxidase technique, original magnification = × 250). A. Pleomorphic adenoma, depicting very weak staining (arrow). B. Only one primary non metastasizing adenoid cystic carcinoma was positive for CD105 staining, of weak intensity (arrow). C. Adenoid cystic carcinoma, primary metastasizing lesion, depicting clear and strong positivity around and within tumoral nests (arrows). D. Polymorphous low-grade adenocarcinoma, primary non-metastasizing lesion, with strongly positive vessels (arrow) permeating tumoral strands. E. Mucoepidermoid carcinoma, primary non-metastasizing lesion, with strongly positive vessels (arrows) around tumoral nests. F. Mucoepidermoid carcinoma, primary metastasizing lesion, evidencing numerous and strongly positive vessels (arrows) intermingling tumoral parenchima.